Literature DB >> 20032407

In vitro effects of dichloroacetate and CO2 on hypoxic HeLa cells.

K M Anderson1, J Jajeh, P Guinan, M Rubenstein.   

Abstract

HeLa and PANC-1 cells were exposed to conflicting signals promoting anaerobic or aerobic energy-generating processes and their viability, cell numbers and the ability of HeLa cells to form colonies were assessed. Under conventional aerobic cell culture with 5% CO(2), dichloroacetate (DCA), an inhibitor of the enzyme pyruvate dehydrogense kinase with subsequent stimulation of pyruvate dehydrogenase that redirects energy metabolism toward the Kreb cycle, reduced HeLa and PANC-1 cellular proliferation and viability. With nitrogen-induced hypoxia, the number of control cells and cells cultured with 12.5 mM DCA paradoxically was greater than that of normoxic controls under similar conditions. A higher medium pH of cells cultured under nitrogen contributed to these differences. In 96-well experiments, 95% nitrogen with 5% CO(2) reduced the numbers of hypoxic cells and medium pH toward that of the aerobic controls, with retention of the DCA-induced hypoxic compared to normoxic cell numbers. The media of these cells cultured with DCA still exhibited an increased pH. Increased hypoxia-inducible factor 1, alpha subunit (HIF1A) mRNA expression in hypoxic HeLa cells and their greater reliance on D-glucose for metabolic energy confirmed the reliability of the incubation conditions. Compared with normoxic cells, hypoxic cells initially increased their synthesis of ATP, but once proliferation ceased, this no longer closely correlated with cell numbers. Type 1 apoptosis, which was somewhat greater in hypoxic than normoxic cells, contributed to hypoxia and DCA-induced cell death. Colony counts of hypoxic, DCA-inhibited cells subsequently switched to normoxia exceeded those of similarly treated normoxic DCA cells. Despite inhibition in certain hypoxic environments of pyruvate dehydrogenase kinase by DCA and its contribution to increased cellular apoptosis and necrosis, hypoxic cells generally outnumbered normoxic control cells, as did hypoxic DCA-treated cells compared with comparable DCA-treated normoxic cells. Since in vivo hypoxic cells are considered a major factor contributing to therapeutic failure, and as DCA redirects energy metabolism toward the more energy efficient Kreb citric acid cycle, associated with increased medium (and inferred cellular) pH, similar circumstances in vivo could promote proliferation and survival of hypoxic cell clones with the potential for developing unwanted properties.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20032407

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  14 in total

1.  Human polymorphisms in the glutathione transferase zeta 1/maleylacetoacetate isomerase gene influence the toxicokinetics of dichloroacetate.

Authors:  Albert L Shroads; Taimour Langaee; Bonnie S Coats; Tracie L Kurtz; John R Bullock; David Weithorn; Yan Gong; David A Wagner; David A Ostrov; Julie A Johnson; Peter W Stacpoole
Journal:  J Clin Pharmacol       Date:  2011-06-03       Impact factor: 3.126

2.  Comparison of In Vitro Chlamydia muridarum Infection Under Aerobic and Anaerobic Conditions.

Authors:  Ira M Sigar; Amber Kaminski; Brent Ito; Jayme Christoffersen-Cebi; Aleksandra Vidovich; Celinne Macarulay; Erris Rowan; Balbina J Plotkin
Journal:  Curr Microbiol       Date:  2020-04-06       Impact factor: 2.188

3.  Normoxic or hypoxic CD44/CD41 a₂ B₁ integrin-positive prostate PC3 cell side fractions and cancer stem cells.

Authors:  K M Anderson; P Guinan; M Rubenstein
Journal:  Med Oncol       Date:  2013-12-10       Impact factor: 3.064

Review 4.  Glucose metabolic phenotype of pancreatic cancer.

Authors:  Anthony K C Chan; Jason I E Bruce; Ajith K Siriwardena
Journal:  World J Gastroenterol       Date:  2016-03-28       Impact factor: 5.742

5.  Bicarbonate and dichloroacetate: evaluating pH altering therapies in a mouse model for metastatic breast cancer.

Authors:  Ian F Robey; Natasha K Martin
Journal:  BMC Cancer       Date:  2011-06-10       Impact factor: 4.430

6.  In vitro cytotoxicity of combinations of dichloroacetate with anticancer platinum compounds.

Authors:  Ulrike Olszewski; Thomas Tuxen Poulsen; Ernst Ulsperger; Hans Skovgard Poulsen; Klaus Geissler; Gerhard Hamilton
Journal:  Clin Pharmacol       Date:  2010-09-14

7.  NMR-based evaluation of the metabolic profile and response to dichloroacetate of human prostate cancer cells.

Authors:  Mithun Kailavasan; Ishtiaq Rehman; Steven Reynolds; Adriana Bucur; Gillian Tozer; Martyn Paley
Journal:  NMR Biomed       Date:  2014-03-17       Impact factor: 4.044

8.  Long-term stabilization of stage 4 colon cancer using sodium dichloroacetate therapy.

Authors:  Akbar Khan; Douglas Andrews; Anneke C Blackburn
Journal:  World J Clin Cases       Date:  2016-10-16       Impact factor: 1.337

9.  Dichloroacetate reverses the hypoxic adaptation to bevacizumab and enhances its antitumor effects in mouse xenografts.

Authors:  Krishan Kumar; Simon Wigfield; Harriet E Gee; Cecilia M Devlin; Dean Singleton; Ji-Liang Li; Francesca Buffa; Melanie Huffman; Anthony L Sinn; Jayne Silver; Helen Turley; Russell Leek; Adrian L Harris; Mircea Ivan
Journal:  J Mol Med (Berl)       Date:  2013-01-30       Impact factor: 4.599

10.  A comparative analysis of inhibitors of the glycolysis pathway in breast and ovarian cancer cell line models.

Authors:  Chrysi Xintaropoulou; Carol Ward; Alan Wise; Hugh Marston; Arran Turnbull; Simon P Langdon
Journal:  Oncotarget       Date:  2015-09-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.